Unterehmen auf Watchlist setzen
RaySearch Labs
ISIN: SE0000135485
WKN: 905265
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

RaySearch Labs · ISIN: SE0000135485 · PR Newswire (ID: 20240816IO85529)
16 August 2024 08:36AM

RaySearch Laboratories: Interim report April - June 2024


STOCKHOLM, Aug. 16, 2024 /PRNewswire/ -- 

SECOND QUARTER (APRIL- JUNE 2024)      

  • Order intake SEK 290.3 M (239.2)
  • Net sales SEK 318.9 M (239.5)
  • Operating profit SEK 79.3 M (18.2)
  • Profit after tax SEK 61.4 M (10.9)
  • Earnings per share before/after dilution SEK 1.79 (0.32)
  • Cash flow from operating activities SEK 154.6 M (67.2)
  • Order backlog SEK 1,790.5 M (1,954.9) at the end of the period

HALF-YEAR (JANUARY- JUNE 2024)

  • Order intake SEK 528.8 M (445.8)
  • Net sales SEK 576.1 M (469.6)
  • Operating profit SEK 125.1 M (41.9)
  • Profit after tax SEK 98.1 M (28.5)
  • Earnings per share before/after dilution SEK 2.86 (0.83)
  • Cash flow from operating activities SEK 321.9 M (220.9)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

  • Raigmore Hospital in Scotland selects RayCare.
  • RaySearch and C-RAD sign collaboration agreement.
  • RayCare has been certified to be interoperable with Varian TrueBeam.
  • RayStation Used for First-Ever Radiotherapy Treatment with Hitachi's OXRAY system.
  • The New York Proton Center expands their RayStation installation.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

There have been no significant events after the end of the reporting period.

WEBCAST

CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for April-June 2024 in a webcast to be held in English on Friday, August 16, 2024, at 10:00 a.m. CEST.

Link to webcast: RaySearch Q2, 2024

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 16, 2024, at 7:45 a.m. CEST.

For more information, please contact:

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)

Telephone: +46 (0) 8 510 530 00

johan.lof@raysearchlabs.com

Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)

Telephone: +46 (0) 8 510 530 00

annika.henriksson@raysearchlabs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/interim-report-april---june-2024,c4025135

The following files are available for download:

https://mb.cision.com/Main/1102/4025135/2947903.pdf

RaySearch Interim report Q2 2024

 

Cision View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-april---june-2024-302224207.html

SOURCE RaySearch Laboratories

Visuelle Wertentwicklung / Kursverlauf · RaySearch Labs
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942